Payment overview · 2025
General Payments
$152.90
8 reported records · 5 companies
Healthcare provider profile · identity verified
Theodore Ende, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · FORKED RIVER, NJ · NPI 1093722480
Verified facts
What the public records show
CMS Open Payments records show Theodore Ende, D.O. received $152.90 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.72 | 40.4% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.47 | 23.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.26 | 14.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.41 | 11.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.04 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $152.90 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.79 | 3 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $35.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 73 |
| Alprazolam | Alprazolam | 204 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 52 |
| Metformin Hcl | Metformin Hcl | 143 | 45 |
| Ezetimibe | Ezetimibe | 136 | 46 |
| Tramadol Hcl | Tramadol Hcl | 129 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 31 |
| Losartan Potassium | Losartan Potassium | 118 | 34 |
| Lisinopril | Lisinopril | 106 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 32 |
| Clonazepam | Clonazepam | 101 | 21 |
| Omeprazole | Omeprazole | 100 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 30 |
| Gabapentin | Gabapentin | 94 | 24 |
| Trazodone Hcl | Trazodone Hcl | 93 | 23 |
| Potassium Chloride | Potassium Chloride | 90 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 21 |
| Famotidine | Famotidine | 75 | 26 |
| Furosemide | Furosemide | 75 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 30 |
| Allopurinol | Allopurinol | 71 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 22 |
| Azithromycin | Azithromycin | 68 | 50 |
| Lorazepam | Lorazepam | 66 | 17 |
| Valsartan | Valsartan | 66 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 11 |
| Irbesartan | Irbesartan | 62 | 20 |
| Sertraline Hcl | Sertraline Hcl | 61 | 17 |
| Jardiance | Empagliflozin | 60 | 15 |
| Farxiga | Dapagliflozin Propanediol | 57 | 19 |
| Meloxicam | Meloxicam | 56 | 14 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Simvastatin | Simvastatin | 56 | 15 |
| Eliquis | Apixaban | 51 | 17 |
| Glipizide | Glipizide | 49 | 14 |
| Spironolactone | Spironolactone | 49 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 16 |
| Carvedilol | Carvedilol | 46 | 17 |
| Telmisartan | Telmisartan | 46 | 13 |
| Cefuroxime | Cefuroxime Axetil | 44 | 37 |
| Lactulose | Lactulose | 42 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Diazepam | Diazepam | 39 | 13 |
| Glimepiride | Glimepiride | 39 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | 12 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 18 |
| Hydromorphone Hcl | Hydromorphone Hcl | 27 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.90 · 8 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CLOSUREFAST, Cologuard Collection Kit, FARXIGA, GEMTESA, ZORYVE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error